serum
antibodi
human
coronaviru
differ
age
group
measur
complement
fixat
cf
haemagglutin
inhibit
hi
radial
diffus
haemolysisingel
hig
solidphas
radioimmunoassay
ria
method
antigen
grown
suckl
mous
brain
use
test
result
obtain
cf
hig
test
ria
good
agreement
regard
presenc
absenc
antibodi
similar
result
also
obtain
hi
test
nonspecif
haemagglutin
inhibitor
first
remov
treatment
phospholipas
c
titer
greater
consid
posit
children
month
age
n
without
measur
coronaviru
antibodi
four
assay
rapid
increas
preval
antibodi
occur
subsequ
age
group
practic
person
year
age
older
found
antibodi
measur
hig
test
ria
mean
antibodi
level
determin
two
method
continu
increas
howev
age
group
year
increas
antibodi
level
initi
antibodi
incid
plateau
may
due
boost
effect
caus
relat
coronaviru
strain
sinc
antigen
known
crossreact
antibodi
induc
human
coronavirus
taken
togeth
data
suggest
viru
antigen
relat
coronaviru
strain
common
finland
coronavirus
tyrrel
caus
seriou
infect
mani
anim
speci
exampl
hepat
enceph
mice
bronchiti
chicken
encephalomyel
piglet
sever
gastroenter
calv
piglet
refer
see
mcintosh
hierholz
contrast
coronaviru
strain
isol
man
associ
mild
upper
respiratori
tract
infect
bradburn
tyrrel
present
knowledg
epidemiolog
real
clinic
signific
human
coronavirus
may
superfici
howev
due
technic
difficulti
diagnos
coronaviru
infect
bradburn
tyrrel
inde
coronavirus
may
also
caus
nonrespiratori
diseas
man
sinc
recent
report
associ
nonbacteri
gastroenter
caul
clark
endem
neohriti
iauostolov
et
al
seroepidemiolog
studi
human
coronaviru
antibodi
carri
use
viru
strain
bradbourn
tyrel
antigen
strain
adapt
grow
suckl
mous
brain
readili
produc
haemagglutinin
kay
dowdl
haemagglutin
inhibit
hi
antibodi
thought
rel
specif
strain
survey
use
viru
hi
test
suggest
viru
common
agent
mani
countri
bradburn
tyrrel
kay
et
al
bradburn
somerset
zakstelskaya
et
al
riski
estola
complementfix
cf
antigen
produc
viru
mous
brain
hand
broadli
crossreact
antibodi
elicit
human
coronaviru
strain
bradburn
tyrrel
suggest
cf
antigen
may
suitabl
use
groupantigen
gener
diagnosi
coronaviru
infect
alenc
viru
strainrel
antibodi
differ
age
group
compar
purpos
antibodi
measur
convent
cf
hi
serolog
techniqu
well
recent
develop
radial
diffus
haemolysisingel
hig
solidphas
radioimmunoassay
ria
method
start
survey
coronaviru
infect
finland
report
prev
sera
patient
select
evenli
cover
age
group
month
less
year
age
specimen
origin
collect
serolog
diagnosi
suspect
viral
infect
store
meanwhil
kindli
made
avail
routin
diagnost
laboratori
depart
virolog
univers
helsinki
mous
brainadapt
viru
kay
dowdl
propag
describ
previous
ski
et
al
infect
brain
homogenis
vigor
pipet
ten
volum
cold
melnick
medium
suspens
form
centrifug
minut
clarifi
supernat
store
use
antigen
cf
hi
hig
test
virusinfect
uninfect
brain
antigen
prepar
use
ria
pool
brain
materi
place
sodium
phosphat
ph
contain
nacl
pb
cell
disrupt
stroke
tightfit
glass
homogen
suspens
centrifug
ooog
minut
pellet
obtain
resuspend
pb
store
upon
thaw
homogen
suspens
obtain
sonic
protein
concentr
determin
method
lowri
et
use
bovin
serum
albumin
bsa
standard
standard
method
palmer
casey
j
bradburn
tyrrel
use
minor
modif
serial
twofold
dilut
heatinactiv
sera
incub
overnight
unit
antigen
unit
complement
bind
complement
assay
mean
sensit
sheep
red
blood
cell
titer
greater
consid
posit
nonspecif
inhibitor
viru
haemagglutin
first
remov
sera
treatment
phospholipas
c
type
sigma
st
loui
describ
hauken
blom
rubella
viru
nonspecif
hi
inhibitor
serial
twofold
dilut
made
dulbecco
phosphat
buffer
salin
contain
bsa
rat
erythrocyt
buffer
ad
haemagglutin
score
minut
room
temperatur
titer
greater
consid
posit
antigen
kindli
mount
orivir
hig
plate
mr
p
heinonen
mr
vienenen
orion
diagnostica
ltd
helsinki
accord
publish
method
vgninen
et
al
riski
et
al
heatinactiv
sera
pl
pipet
well
hour
diamet
haemolysi
ring
measur
ruler
smallest
haemolysi
ring
score
posit
diamet
mm
procedur
use
adapt
previou
assay
kalimo
et
al
arstila
et
al
iodin
antibodi
human
ig
assay
dilut
buffer
prepar
describ
recent
meurman
ziola
briefli
viru
antigen
control
antigen
dilut
pb
adsorb
polystyren
ball
precis
plastic
ball
co
chicago
concentr
pg
per
ball
overnight
incub
room
temperatur
unadsorb
antigen
remov
ball
airdri
serum
dilut
pl
dispos
plastic
tube
test
duplic
viru
control
antigen
ball
hour
c
unbound
immunoglobulin
aspir
away
ball
wash
twice
ml
tapwat
antibodi
human
igc
heavychainspecif
ad
hour
c
unbound
iodin
antibodi
remov
ball
wash
ball
final
roll
clean
tube
bound
radiolabel
count
wallac
lkb
gamma
counter
preliminari
test
reveal
specif
igg
bind
viru
antigenco
ball
show
prozon
low
dilut
consequ
sera
test
singl
dilut
cpm
differ
viru
control
antigen
ball
use
semiquantit
measur
actual
viru
igg
level
assay
standardz
two
way
first
absolut
amount
iodin
antibodi
human
igg
per
tube
need
give
cpm
bound
incub
hour
ball
adsorb
pg
deaesepharos
chromatographypurifi
human
igg
second
interassay
variat
compens
relat
cpm
differ
serum
specimen
refer
serum
pool
includ
assay
bind
differ
cpm
greater
taken
indic
seroposit
sera
individu
differ
age
test
presenc
coronaviru
antibodi
cf
hi
hig
ria
method
percentag
individu
found
posit
age
group
studi
shown
figur
one
infant
month
age
less
cf
antibodi
titer
viru
similarli
one
infant
hi
antibodi
titer
contrast
hig
test
ria
detect
viru
antibodi
sera
infant
respect
children
two
subsequ
age
group
month
month
neg
viru
antibodi
four
test
prise
children
year
old
fig
age
year
practic
children
antibodi
viru
measur
hlg
test
ria
slightli
lower
posit
incid
obtain
cf
hi
test
high
frequenc
antibodi
posit
seen
age
year
sustain
older
age
group
age
year
thereaft
tendenc
frequenc
declin
observ
rapid
increas
antibodi
preval
observ
three
age
group
comth
mean
viru
antibodi
level
calcul
age
group
shown
figur
mean
antibodi
titer
measur
cf
hl
test
low
sinc
titer
higher
cf
test
hi
test
uncommon
contrast
much
greater
variat
antibodi
level
seen
hig
test
ria
use
tinctiv
pattern
four
antibodi
assay
fig
highest
cf
titer
found
age
year
slight
tendenc
mean
titer
decreas
mean
titer
obtain
hi
test
steadili
increas
group
year
old
remain
constant
drop
seen
age
group
similar
pattern
mean
antibodi
level
obtain
hig
test
chang
mean
antibodi
curv
increasephas
plateauphas
age
group
year
much
distinct
hig
test
hi
test
owe
greater
antibodi
rang
measur
hig
test
appar
biphas
mean
antibodi
curv
obtain
ria
mean
antibodi
level
increas
sharpli
children
month
old
plateau
second
increas
mean
antibodi
level
observ
year
age
mean
antibodi
level
differ
age
group
found
form
di
sever
point
concern
present
result
deserv
comment
obviou
coronaviru
infect
widespread
finland
essenti
everyon
older
year
measur
antibodi
viru
antigen
light
complet
lack
coronaviru
antibodi
unexpect
find
observ
may
explain
two
differ
epidemiolog
situat
either
children
younger
year
contact
coronaviru
infect
like
littl
coronaviru
circul
finland
last
two
year
latter
true
sera
collect
year
ago
children
younger
year
ie
agem
yearold
children
studi
possess
coronaviru
antibodi
much
frequent
found
studi
question
answer
soon
appropri
specimen
assembl
variou
serum
archiv
anoth
epidemiolog
question
aris
age
group
plot
antibodi
frequenc
mean
antibodi
level
compar
antibodi
frequenc
curv
reach
maximum
year
mean
antibodi
level
continu
increas
year
group
differ
readili
seen
hig
test
result
particularli
evid
ria
result
owe
biphas
natur
mean
antibodi
level
curv
suggest
viru
typic
infect
preschool
children
strain
frequent
associ
infect
adolesc
young
adult
bradburn
tyrrel
true
two
rapid
increas
ria
mean
antibodi
number
sera
test
age
group
except
group
month
month
age
number
specimen
respect
hi
haemagglutina
tion
inhibit
cf
complement
fixat
hig
radial
diffus
haemolysisingel
ria
solidphas
radioimmunoassay
age
year
fig
mean
level
coronaviru
antibodi
differ
age
group
two
top
panel
show
geometr
mean
hi
c
f
titr
respect
hig
arithmet
mean
diamet
hemolysi
ring
mm
induc
individu
sera
shown
age
group
ria
sera
test
singl
dilut
bound
quantit
antihuman
ig
figur
shown
arithmet
mean
bound
cpm
vertic
bar
repres
confid
limit
variat
detail
see
method
level
could
due
two
agerel
coronaviru
epidem
like
howev
second
epidem
wave
caus
viru
third
human
coronaviru
strain
sinc
crossreact
strain
strong
ria
instanc
found
sever
sera
rel
high
antibodi
level
viru
react
viru
antigenco
ball
vice
versa
unpublish
result
also
possibl
cours
second
sharp
mean
antibodi
increas
seen
ria
result
simpli
due
reinfect
viru
strain
present
result
provid
evid
presenc
sera
nonspecif
inhibitor
coronaviru
haemagglutin
hovi
exampl
sera
children
month
age
neg
ria
moder
titer
hi
test
sera
pretreat
test
data
shown
phospholipas
c
treatment
howev
complet
remov
nonspecif
inhibitor
sinc
children
month
age
appar
hi
titer
even
treatment
import
aspect
present
studi
concern
comparison
differ
serolog
method
employ
hi
test
use
rel
wide
serolog
screen
viru
antibodi
rooster
red
blood
cell
origin
use
laboratori
titer
viru
haemagglutinin
riski
estola
larg
variat
sensit
erythrocyt
differ
bird
subsequ
found
howev
chang
rat
erythrocyt
made
hovi
also
see
kay
dowdl
use
rat
erythrocyt
phospholipas
c
pretreat
sera
result
accur
reproduc
test
hovi
although
individu
present
studi
coronaviru
hi
antibodi
titer
low
suggest
infect
occur
time
low
hi
titer
present
sera
thu
contrast
moder
high
viru
titer
found
recent
convalesc
sera
titer
variat
found
viru
cf
test
similar
found
hi
test
major
sera
cf
antibodi
titer
higher
rare
case
hi
antibodi
titer
high
measur
certain
convalesc
sera
much
greater
variat
viru
antibodi
level
found
hig
ria
method
use
probabl
reflect
greater
sensit
two
method
compar
hi
cf
test
also
possibl
hig
test
ria
detect
antibodi
viru
antigen
two
older
serolog
method
consequ
apart
use
seroepidemiolog
survey
present
one
hig
ria
method
may
also
valuabl
tool
diagnosi
acut
coronaviru
infect
preliminari
applic
two
assay
regard
yield
promis
result
